Understanding the Current Site Sector Consolidation Trend

The clinical research industry is undergoing a profound transformation, driven by market consolidation and technological innovation. To adapt, clinical research sites are embracing innovation, increased collaboration, and strategic positioning to thrive. The site consolidation trend shows no sign of abating. In this blog post, we caught up with Barry Lake, co-founder at Devana Solutions, a RealTime Software Solutions Company. We wanted to better understand the driving forces behind the site consolidation trend and uncover key investment areas for sites aspiring to accelerate their growth and enhance their appeal to sponsors and investors. 

About our in-house industry expert, Barry Lake, Co-Founder and President of Devana Solutions: Before co-founding Devana Solutions, Barry Lake gained hands-on experience in site operations at a clinical research site in Charleston, South Carolina. In addition to managing his own site, he was part of a management team that established an early “network” of high-performing, independent yet affiliated sites that shared marketing and sales resources. He witnessed the emergence of strategic acquisitions and site consolidations, notably in 2015 when PPD acquired Synexus’s approximately 100+ sites and ICON acquired PMG Research’s 12 U.S. sites. In 2019, ICON further expanded by combining PMG’s U.S. footprint with MeDiNova’s European sites, forming the Accellacare Global Site Network, now comprising approximately 112 sites. 

Interview with Barry Lake

Q: Can you share your background and how it influenced your journey in the clinical trials industry? 

Barry Lake: Before co-founding Devana Solutions, I gained experience in site operations at a clinical research site in Charleston, South Carolina. This first-hand experience of the pain points of running a site, coupled with witnessing the emergence of strategic acquisitions and site consolidations, inspired me to pioneer the Devana Solution platform. Launched in 2016, Devana built a category-defining product that addresses the challenge with study start-up, pipeline management and business intelligence for sites, sponsors, and CROs. 

 

Q: Can you share your observations on the current trends shaping the clinical research landscape, particularly regarding site success and market consolidation? 

Barry Lake: Absolutely. We have been witnessing a significant shift in the clinical research industry, characterized by the consolidation of site networks. Strategic acquisitions and private equity investments are driving this trend, leading to the emergence of larger, integrated site networks. This consolidation presents both opportunities and challenges for sites as they maneuver through the complexities of modern clinical trials.  

Organizations transitioning from “boutique” businesses to sustainable enterprises are leveraging capital to increase their scale and value. Successful execution necessitates securing sufficient capital to sustain competitive advantage and drive growth. In the site sector consolidation, winners emerge by executing profitably and strategically accessing capital. 

If an organization makes the commitment to move beyond being a boutique business towards building truly sustainable enterprise value through a leading position therapeutically or through scale across a geographic footprint, over time, the leadership will face relentless and ever-increasing pressures stemming from their own commercial success. The good news for these site organizations is they will certainly be much more valuable in private equity’s eyes, assuming their leadership is open to leveraging more capital to increase their scale. Successful execution inevitably requires increasingly larger tranches of capital for any organization to sustain a balance sheet that enables them to maintain a competitive advantage and continue scaling and increasing their enterprise value over the long term.  

In other words, when an industry sector consolidates fueled by the efficient deployment of a massive amount of capital at scale (the role of the financial sector in every industry) it envelopes both types of companies in the sector: the losers and the winners. The losers in the clinical trial site sector will be those site organizations that cannot evolve into becoming one of leaders either by not performing profitably or, if they do, in fact, become profitable their ownership fails to seek sufficient capital to shore up their balance sheet and drive their growing dominance.  

I foresee that those organizations that fail to access more capital when they need it will be outmaneuvered over the long run by more savvy competitors with stronger balance sheets. As a result, the site organizations on the wrong side of market forces will either go out of business if they are unprofitable or, if they don’t seek more capital to shore up their balance sheet, be forced to eventually sell at a depressed value to a competitor or industry aggregators. 

The ultimate winners in this consolidation battle will be those site organizations who execute profitably and then attract and, are willing to accept, additional capital on reasonable terms at numerous inflection points along their growth journey. 

 

Q: How does essential site-based technology contribute to site success in this site consolidation market? 

Barry Lake: Technology can be a game-changer for clinical research sites looking to succeed in today’s competitive environment. Electronic solutions that replace error-prone paper-based processes, like Devana, enhance transparency, streamline workflows, and facilitate integration with the industry’s top CTMS providers including RealTime, CRIO and Clinical Conductor. Devana improves site business operations, accelerates study startup processes, and fosters efficiency across the entire clinical trial journey, from study start-up, execution to closeout. By leveraging advanced eClinical technology, sites can improve data accuracy, accountability, and position themselves as leaders within larger site networks. 

 

Q: What are some key strategies that clinical research sites can employ to capitalize on growth opportunities? 

Barry Lake: Strategic positioning is essential for clinical research sites. By focusing on areas of expertise, building strong relationships with sponsors and CROs, and investing in eClinical technology solutions built for clinical trials, sites can enhance their value proposition and attract increased investments. Additionally, collaboration and networking within larger site networks can open doors to new opportunities for growth and expansion. 

 

Q: What role does Devana play in shaping the future of clinical trials? 

Barry Lake: The private equity fueled site sector consolidation has continued to accelerate at a rapid pace heading in 2024 and Devana remains at the forefront of innovative eClinical solutions purpose-built to help sites scale faster. Devana delivers crucial transparency to site leadership and operating managers, shedding light on the upstream pipeline of trial opportunities and automating study startup workflows. In fact, on average, sites that have adopted Devana report 76% reduced contract budget and turnaround time, 14 hours saved in study activation, and 40% increased revenue. 

And the platform continues to shape the future of clinical trials through strategic partnerships like seamless integrations with industry-leading CTMS providers and cutting-edge new features such as our Query Feature, which allows central team members to query all sites within their network based on a given trial’s specific criteria for capabilities, equipment, and more. They can send new trial opportunities directly within PROPEL and receive real-time site responses and turnaround timing metrics in return. 

Today, we partner with many of the industry’s largest site networks to drive efficiency, compliance, and patient engagement. That’s why Devana is humbled to call virtually every major site network a partner-client. In fact, eight of the top 10 site networks in the world have already adopted Devana. The exponential growth of our site network clients spotlights the tangible benefits of leveraging advanced eClinical technology across the entire clinical trials journey.  

Final Thoughts

The momentum behind the site sector consolidation trend is undeniable and continues to gain traction. Whether it’s backing a single large site as a platform investment or spearheading a network roll-up strategy, private equity sponsors are actively seeking opportunities to deploy capital and drive site consolidation efforts.  

At RealTime Software Solutions, our team predicts that the consolidation trend will continue to play out similarly across the site sector as it did from the 1990’s through the early 2020’s in the CRO sector. The site consolidation wave will continue until the site space is largely dominated by only a handful of major global site organizations in much the same manner as just a handful of major global CROs control almost 80% of the pharmaceutical sponsors outsourcing spend on clinical trials that run through CROs. As such, it’s crucial for independent site owners to position themselves as market leaders in their respective fields, recognizing that acquisition by larger networks is inevitable for long-term success. By staying ahead of the curve and strategically investing in growth areas, sites can still emerge as industry leaders. 

Decoding How Sponsors Evaluate Research Sites for Clinical Trials

When selecting clinical research sites for their trials, sponsors look for a blend of capabilities, resources, and a proven track record that promises the best outcomes for their studies. With sponsors seeking top-performing sites that align with their trial objectives, the ability to showcase expertise, efficiency, and reliability is the key component to success. This selection process is crucial as the chosen sites directly impact the efficiency, compliance, and ultimately the outcome of clinical trials.  

In this blog, we’ll explore the key factors that sponsors consider when evaluating potential clinical research sites. From the expertise of the staff and the facility’s infrastructure to patient recruitment strategies and regulatory compliance, understanding what sponsors are looking for can help clinical sites not only meet but exceed these expectations. Whether you’re a seasoned investigator or a site looking to attract more trials, this insight into sponsor priorities will provide valuable guidance on how clinical research sites can use purpose-built technology, like PROPEL, built by Devana Solutions, to demonstrate that they are a high-performing site that stands out in a competitive field. 

Site Experience and Expertise 

One of the primary considerations for sponsors during site selection is experience and expertise. Sponsors prefer sites with a proven track record of successfully conducting similar trials, demonstrated by a history of patient recruitment, retention, and data quality. Additionally, sites and Physician Investigators (PIs) having expertise in specific therapeutic areas or specialized procedures relevant to the trial protocol is also highly valued.   

By centralizing data management, PROPEL is a pioneering platform that enables sites to efficiently track and report on key performance metrics. This consolidation of data within a single system streamlines operations, offering unprecedented visibility into trial progress and site performance. With its powerful analytics and reporting capabilities, PROPEL enables research sites to transparently showcase their past and current performance metrics to sponsors. From patient recruitment statistics in a given indication to site activation timelines, PROPEL generates customizable reports highlighting a site’s efficiency and effectiveness.  With PROPEL, sites can effectively monitor their performance, identify areas for improvement, and demonstrate their capabilities to sponsors with unparalleled precision and efficiency. Sponsors appreciate sites that can provide transparent and timely performance data, as it allows them to make informed decisions when selecting partners for their trials. Moreover, this transparency enhances the site’s reputation and ultimately strengthens the overall partnership between sites and sponsors. 

Patient Population and Recruitment Potential 

Patient retention and recruitment is another pivotal factor for success in clinical trials. Access to diverse patient pools is particularly important. Clinical research sites are assessed by sponsors based on their access to the target patient population and their innovative strategies for patient recruitment. 

In recent years, there has been a growing mandate to improve diversity in clinical trial populations. This push is driven by the recognition that diverse populations may respond differently to treatments, which has significant implications for the generalizability of trial results. In fact, regulatory bodies like the FDA in the United States have issued guidelines that encourage the inclusion of varied demographic groups in clinical trials to ensure that the findings are applicable to a broader population. These guidelines recommend that trial designs consider factors such as age, gender, and racial and ethnic backgrounds. Sites that have established relationships with patient communities often have an advantage. These relationships facilitate trust and communication, which are crucial for encouraging participation and ensuring participants remain engaged throughout the trial.   

Sponsors value sites that can leverage past and real-time data analytics to drive continuous improvement and ensure the success of their trials. PROPEL’s advanced analytics capabilities provide clinical research sites with invaluable insights into trial performance. By analyzing site metrics, patient recruitment trends, and operational efficiency indicators, sites can make data-driven decisions that optimize trial strategies and resource allocation. Additionally, sites can track which patient recruitment methods have worked the best in the past to inform future decisions. Plus, PROPEL’s seamless integrations with the leading CTMS providers allows for a full-cycle view of past trial performance and patient recruitment.  

Site Facility and Resources 

The physical infrastructure and resources available at a site are carefully evaluated by sponsors. This includes the availability of state-of-the-art facilities for patient visits, laboratory capabilities for sample processing, and access to necessary equipment and technology. Adequate staffing, including trained research personnel and support staff, is essential for efficient trial conduct.  

Using comprehensive site profiles, PROPEL makes it easy to see all the key capabilities, equipment, and staff members in one place. For larger site networks, PROPEL enables central teams to query all their sites and filter by specific criteria, including equipment and therapeutic specialties. This makes it easy for research site organizations of all sizes to respond quickly to sponsors about how their available resources match up to the trial opportunity.

Regulatory Compliance and Quality Assurance 

Sponsors are increasingly vigilant about regulatory compliance, given its impact on the integrity and validity of trial results. Sites that can demonstrate that they prioritize and manage regulatory aspects effectively are often more attractive to sponsors. This includes compliance with Good Clinical Practice (GCP) guidelines, adherence to protocol requirements, and timely reporting of adverse events. Sites with robust quality assurance processes and a culture of continuous improvement tend to be favored by sponsors.  

PROPEL simplifies regulatory compliance for sites, offering a comprehensive platform for tracking all necessary regulatory documents. The platform includes automated compliance workflows, which significantly reduces the potential for human error and improves the efficiency of compliance processes. Furthermore, PROPEL provides detailed audit trails for sites to consistently verify and document their compliance status throughout the clinical trial process. Altogether, PROPEL helps sites demonstrate their commitment to maintaining high-quality standards. 

Budget and Contract Negotiation 

While not the sole determining factor, budget considerations play another significant role in site selection. Sponsors evaluate potential sites based on their proposed budgets, which include personnel costs, overhead expenses, and any additional services required. Additionally, a site’s negotiation skills and their ability to offer flexible contract terms can also influence site selection decisions.  

PROPEL further optimizes trial management by centralizing tasks and automating many routine workflows, thereby improving efficiency, reducing the administrative burden, saving time and money, and minimizing errors. The platform’s ability to capture real-time data allows research sites to document these efficiencies and cost savings through detailed reports and key performance indicators (KPIs). This capability helps sites distinguish themselves in a competitive field.  Sponsors are drawn to sites that can demonstrate streamlined operations, as it signifies a commitment to excellence and a focus on delivering high-quality data within stipulated timelines. 

Communication and Collaboration 

Effective communication and collaboration between sponsors and clinical research sites are essential for the smooth conduct of clinical trials. Sponsors further evaluate sites based on their responsiveness, transparency, and willingness to collaborate on trial-related activities. Sites that demonstrate proactive communication and a commitment to addressing sponsor concerns are more likely to be selected as effective collaboration is a cornerstone of successful clinical trials.   

PROPEL is purpose-built to facilitate seamless communication and collaboration among site teams, sponsors, CROs, and other stakeholders. Real-time sharing of information, progress updates, and feedback fosters a collaborative environment that instills confidence in sponsors. Sites that leverage PROPEL to enhance collaboration and data-sharing are more likely to stand out to sponsors seeking reliable partners. 

Stand Out with PROPEL 

Selecting the right clinical research sites is a critical step in the success of clinical trials. Sponsors carefully evaluate sites based on various factors, including experience, patient recruitment potential, facilities, and more. Devana Solutions’ one-of-a-kind PROPEL platform empowers sites to elevate their performance and stand out to sponsors. By streamlining and automating operations, enhancing collaboration, enabling data-driven decision-making, ensuring regulatory compliance, and providing transparent performance metrics, PROPEL equips sites with the tools they need to showcase their expertise and reliability. As sponsors seek out top performing sites to partner with, PROPEL emerges as a key differentiator that enables research sites to shine and win more trial opportunities from sponsors and CROs.  

Devana Solutions  

A RealTime Software Solutions Company, Devana Solutionsis an innovative cloud-based clinical trial software provider that supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana Solutions even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems.   

Let us show you in more detail what Better Data, Better Decisions, Better Outcomes could do for your clinical trial processes.Book a demo with Devana Solutions today to learn about our cloud-based data analytics clinical trial software for the clinical trials industry that integrates seamlessly with CTMS and other key systems to keep success in the crosshairs.  

Read More: Case Study – Accellacare (ICON’s Global Site Network) & Oncacare (specialized oncology site network) 

Devana Solutions CEO Barry Lake on Note to File Podcast

Devana Solutions CEO Barry Lake recently sat down with Brad Hightower of the Note to File Podcast to discuss the current state of the industry and the importance of sites tracking their own metrics using clinical trial software like Devana Solutions.

Offering holistic trial analysis and a dynamic site and investigator database, Devana Solution’s enterprise software gives businesses the crucial support and data management they need to focus on their own business efforts and core competencies. We understand the unique challenges of the clinical trials industry and offer comprehensive solutions such as automated data evaluation and communication, freeing teams from repetitive tasks so they can focus on winning more study contracts.

For life-saving therapies and vaccines to reach patients more quickly, leading research organizations turn to Devana Solutions for cutting-edge cloud-based SaaS technology and services in the clinical trial industry.

Check out Barry’s episode of the Note to File Podcast here.

Note to File Podcast

Note to File is a podcast for clinical research sites, featuring interviews, best practices, and candid commentary from host Brad Hightower, founder of Hightower Clinical and clinical research professional. The podcast was born with the hope of providing a resource for research professionals to share their stories and serve as a source for practical advice for the clinical research community.

Devana Solutions

Devana Solutions is an innovative cloud-based clinical trial software company that supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana Solutions even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems.

Let us show you in more detail what Better Data, Better Decisions, Better Outcomes could do for your clinical trial processes. Book a demo with Devana Solutions today to learn about our cloud-based data analytics clinical trial software for the clinical trials industry that integrates seamlessly with CTMS and other key systems to keep success in the crosshairs.

Improve Study Outcomes with Clinical Trial Software for CROs

The relationship between sponsors and contract research organizations (CROs) is strengthening as outsourcing becomes a clinical trial norm. It is important for the CRO to have a good working relationship with sites in order to ensure that the trial is successful, particularly in the study startup phase, as clinical trials are increasingly expensive and time-consuming endeavors.

Key factors that influence a good relationship and where clinical trial software can help are:

  • Targeted Site Selection
  • Digitized Feasibility
  • Enhanced Site Collaboration and Communication
  • Process and Performance Transparency

Targeted Site Selection

More complex protocols require more precise site selection. Devana’s PROPEL technology allows for CROs to perform automated queries during site selection to determine the right sites or investigators based on the requirements of the protocol. PROPEL allows CROs to store the site and investigator performance and capabilities data that can be managed and updated by the sites, in real-time, allowing for more accurate site selection. Sponsors can be confident that the sites selected by the CRO will be capable of meeting performance expectations, resulting in better study outcomes.

Digitized Feasibility

While feasibility questionnaires are certainly a critical piece to selecting the right sites for a trial, the entire process, as it is today, is a bit archaic. Devana is revolutionizing the feasibility process by allowing CROs to submit a digitized feasibility to the sites selected for each trial. Say goodbye to outdated PDFs and third-party websites. This digital feasibility will pre-populate information that typically remains the same, trial to trial, such as the site’s location and contact information, but allows for the CROs to receive new, trial-specific data such as subject population criteria. The sites can review their previously submitted data for accuracy and respond to any new inquiries, resulting in a speedier feasibility process and a lower cost for the Sponsor.

Enhanced Site Collaboration and Communication

In addition to improving the feasibility process, Devana took it a step further by creating a threaded communication feed between the sites and CROs within the PROPEL platform. If a Sponsor reaches out to a CRO about a trial in bid-defense, needing to quickly know the potential subject pool for a particular indication, the CRO can instantly push out a mass communication to the sites and gather their responses within the platform. No more cumbersome calls or emails to track. Just the same, if a CRO submits a site for a trial, the site can review the details and provide feedback to the CRO or ask questions related to the protocol. It’s a win-win for all involved, the site, the CRO and the Sponsor, since this connectivity allows for more efficient communication throughout the entire clinical trial process.

Process and Performance Transparency

Another important aspect of a good working relationship between Sponsors and CROs is process and performance transparency. The entire clinical trial process, from study startup through close-out, produces a lot of key data. By using PROPEL, CROs have real-time views into the trial, by site, to know exactly where the trial is at any given time. The ability to quickly obtain this data and provide to Sponsors is critical to the swift and successful execution of a trial and the ability to mitigate risk.

Devana Solutions

Devana Solutions is an innovative cloud-based clinical trial software company that supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana Solutions even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems.

Let us show you in more detail what Better Data, Better Decisions, Better Outcomes could do for your clinical trial processes. Book a demo with Devana Solutions today to learn about our cloud-based data analytics clinical trial software for the clinical trials industry that integrates seamlessly with CTMS and other key systems to keep success in the crosshairs.

Boost Study Contract Wins in the Clinical Trial Industry

Is your clinical trial organization looking to boost study contract wins and shorten the sales cycle? Then you need to ensure you have the right tools in your tech stack. In the age of technology, there are many options available but one you must include is a trial startup software that synchronizes your communication and data for increased efficiency.

A quality trial startup technology solutions provider, like Devana Solutions, will understand the unique challenges of the industry and offer comprehensive solutions such as automated data evaluation and communication that frees the sales team from repetitive tasks so they can focus on winning the study contract.

Devana Solutions Saves Time and Shortens Sales Cycles

By eliminating repetitive tasks, Devana Solutions’ PROPEL platform is able to shorten the overall sales cycle. Put an end to the tedious work in spreadsheets or disparate systems, as PROPEL is able to automate sales processes, capture a complex chain of emails, and account for customized variations.

In addition, PROPEL allows for each cross-functional team to seamlessly communicate with one another and understand what stage the trial is in during the startup process. The best software will be easily accessible to every decision-maker across the trial management process.

How Trial Software Software Boosts Sales in the Clinical Trial Industry

Increased data means more informed decision-making. With a vibrant and dynamic site and investigator database, as well as up to date performance metrics, the sales team is able to focus their efforts to determine the best trial opportunities for their organization. Increased data streams allow the organization to predict how their business development strategies will affect their overall operations.

Choosing the Best Trial Startup Software for Your Clinical Trial Business

The best clinical trial software will be one that is designed with the unique challenges of the clinical trials industry in mind. Offering holistic trial analysis and a dynamic site and investigator database, Devana Solutions’ PROPEL enterprise software gives businesses the crucial support they need to focus their business efforts for much success.

Sign up for a free demo and learn what makes PROPEL the best in the industry.

Devana Solutions

Devana Solutions is an innovative cloud software company that supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana Solutions even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems.

Let us show you in more detail what Better Data, Better Decisions, Better Outcomes could do for your clinical trial processes. Book a demo with Devana Solutions today to learn about our cloud-based data analytics software for the clinical trials industry that integrates seamlessly with CTMS and other key systems to keep success in the crosshairs.

2022 World Vaccine Congress: What to Expect

Devana Solutions executives are attending the 2022 World Vaccine Congress in Washington D.C., on April 18-21, 2022. Here’s what leaders in the biopharma industry can expect.The World Vaccine Congress, in existence for over two decades, has grown to become the largest and most established conference dedicated to vaccines, globally. The World Vaccine Congress 2022 will bring together thousands of industry experts across the entire vaccine landscape, with key sessions dedicated to the fight against COVID-19. Taking place April 18-21 at the flagship hotel, Marriott Marquis Washington, DC, the event will be one of the first opportunities to meet in person since the pandemic began to learn, share experiences and ground-breaking knowledge, and network with others who are working against COVID-19 and on other important vaccines.

“If there is anything that the last two years have taught this industry, it’s that the pandemic has certainly put the focus on the need for cutting-edge research to produce more and better vaccines,” Devana Solutions CEO and Co-Founder Barry Lake.

Inside Peek: 2022 World Vaccine Congress Washington

An event that prides itself on covering every subject across the entire vaccine value chain, here is what to expect if you are attending:

  • Visionary Presenters
  • Engaging Agenda
  • Networking Breaks
  • Vaccine Excellence Awards

Visionary Presenters

This year’s presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism, and insight. Just a handful of speakers at the World Vaccine Congress include:

Engaging Agenda

From basic research to commercial manufacture, World Vaccine Congress covers the whole vaccine value chain where science, government and manufacturers all come together to create ground-breaking progress. If you are involved in vaccines or new to it because of the pandemic, World Vaccine Congress is the most important meeting you will be part of in 2022.

Here are some of the topics discussed each day:

April 18

  • Biodefense and preparedness
  • Maternal immunization
  • Vaccine Technology
  • Antimicrobial resistance
  • Antibodies in treating COVID and infectious diseases
  • HIV

April 19

  • Plenary Sessions
  • Interactive roundtable discussions
  • Evening drinks & ViE Awards Dinner

April 20 & 21

  • COVID, influenza and other respiratory diseases
  • Immune profiling
  • Cancer immunotherapy
  • One health and veterinary vaccines
  • Clinical trials and development
  • Manufacture
  • Safety
  • Market access
  • Supply & logistics
  • Newly infectious and chronic diseases

Networking

Being the first in-person World Vaccine Congress since 2020, networking is an essential part of the conference experience. You can find new opportunities to collaborate or meet other people in your field. With over 30 scheduled networking events, from coffee breaks to luncheons, there is ample opportunity to learn and network with colleagues across the industry.

Vaccine Excellence Awards

On Tuesday, April 19th, the World Vaccine Congress will be hosting the 15th Annual Vaccine Industry Excellence Awards Ceremony & Dinner. The Scientific Advisory Board members will help make the final decision in each category, and the winners will be announced at the dinner.

“Devana Solutions is proud to have supported many of the leading vaccine research site organizations that stepped up in a big way during the COVID pandemic, including hyperCORE International, Benchmark Research, Centricity Research, Javara Research, Velocity Clinical Research and Accel Research Sites. We wanted to be in Washington, D.C. to support many of these clients nominated for well-deserved Vaccine Excellence Awards,” said Lake.

Are you planning on attending the 2022 World Vaccine Congress Washington? We’d love to chat. Devana Solutions’ CEO and Co-founder Barry Lake and Director, Strategic Partnerships, Emily Hardy, will be attending the show in the nation’s capital and are available to discuss how technology can improve your clinical trial management process. Connect with Barry or Emily on LinkedIn or use the contact form at the bottom of the page to set something up before the big event!

Devana Solutions Enhances Advisory Board with Addition of Velocity Clinical Research’s Craig Koch

[Chapel Hill, NC, March 17, 2022] Devana Solutions, the leading cloud SaaS provider to the clinical trials industry to connect centralized research professionals to staff and clinicians at decentralized site locations, announced today that industry veteran Craig Koch has joined Devana’s Advisory Board. Koch is currently Executive Vice President of Velocity Clinical Research, a leading integrated research organization in the U.S. with global expansion now underway. Koch will join current Syneos Health Senior Vice President Tom Wollman and longtime software investor and advisor Reid Conrad currently on Devana’s Advisory Board.

“I am delighted to have Craig join our Advisory Board,” stated Barry Lake, Devana Solutions’ CEO, “Velocity Clinical Research is perhaps the most optimized organization now leveraging our advanced PROPEL enterprise platform, and Craig’s analytical skills and leadership are a big reason why. I look forward to his contributions as an advisor to Devana Solutions, particularly with the transformative development initiatives Devana will be delivering to the industry in 2023.”

“Devana Solutions’ began as a tool for clinical research sites where it will remain the gold standard for research site productivity. The flexibility of the platform and the talent of the team also position Devana to be a Solution poised to unify what is a very disjointed industry.”

Founded in 2017, Velocity has grown dramatically in the last few years and now comprises 30 research sites across the United States with current global expansion underway. The Velocity model represents a new approach to site management. By owning and operating all sites directly, the organization offers a robust infrastructure that completely integrates the sites with singular systems and processes. Their model has proven to provide consistent and predictable patient recruitment and engagement. From a systems perspective, Velocity is an extremely technology-enabled organization, and under Koch’s direction, the Devana Solutions platform lies at the heart of Velocity’s business development, feasibility, and pre-award workflows, and both trial enrollment and overall business performance analytics.

According to Lake, “Craig’s expertise in leveraging our technology and industry insights will be a strong addition to Devana’s Advisory Board and our company. I look forward to his contributions.”

About Devana Solutions

Decentralized clinical trials and work-from-anywhere is now a reality. Devana Solutions’ innovative cloud platform supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems. From pipeline administration to rapid study startup automation. From document-sharing through the capture, display, analysis, and exchange of key trial performance metrics data from central research leaders to decentralized trial teams. From investigative site to CRO to trial sponsor, Devana Solutions is the answer. At Devana Solutions, we’re transforming the business of clinical trials. https://devanasolutions.com/

About Velocity Clinical Research

Velocity Clinical Research, headquartered in Durham, NC, is the leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity supports global drug development in primarily conducting phase II and phase III clinical trials. The company has 30 U.S. locations across 14 states. Velocity places the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 7,000 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality. For more information. visit our website at https://velocityclinical.com.

Devana Solutions Connects Research Operations and Business Intelligence at Scale with Clinical Conductor Integration

A new interface between Devana’s IGNITE and PROPEL products and Advarra’s Cloud-Based Clinical Trial Management System establishes an end-to-end solution for efficient research conduct and world-class business intelligence.

CHAPEL HILL, NC (March 10, 2022)Devana Solutions is pleased to announce a new, at scale CTMS- integration solution for research organizations utilizing Advarra’s Clinical Conductor Clinical Trial Management System (CTMS), improving efficiency, and providing research sites with actionable insights across their entire research portfolio.

The Devana <-> Advarra integration is a dynamic, bi-directional data and process flow between Devana’s IGNITE and PROPEL products, and Advarra’s industry-leading Clinical Conductor CTMS. Following the natural progression of a trial, the trial startup begins in Devana, flows through Clinical Conductor for clinical execution and research operations management, and then back to Devana for end-to-end business intelligence. Enrollment performance metrics are derived automatically and pulled into the Devana system as research teams are interacting with Clinical Conductor, reducing duplicative workflows within the systems.

The robust and sought-after analytics, available within the Devana systems, offer configurable views to analyze performance data, by trial or indication, by site, or organization-wide. Combined with Clinical Conductor’s ability to optimize operational finances, regulatory compliance, and overall operational workflows, these integrated products provide a seamless, comprehensive, clinical research solution. After a very thorough and thoughtful technical approach, the Devana <-> Advarra CTMS integration is now live for all Clinical Conductor customers.

“At Devana Solutions, we have always prided ourselves in listening to our clients and being attentive to their needs,” explained Barry Lake, Devana Solutions’ CEO. “So, when the leadership at highly-valued client-partners, Javara Research and Velocity Clinical Research, encouraged an API-integration with Advarra’s Clinical Conductor CTMS to better support their study teams, we were eager to explore it.”

“We were pleased to work closely with the team at Advarra and the integration of both systems has increased our clients’ operational efficiency. We look forward to deploying the connection for the benefit of additional mutual clients. Working together, as an industry, we can and will move mountains!” added Lake.

“We are thrilled to collaborate with Devana and our customers on this innovative interface,” said James Wurdeman, Chief Product Officer at Advarra. “Devana’s approach to developing this integration aligns with our philosophy of creating site-centric, open, customer-focused technology solutions that can be integrated with enterprise systems across a research site or site network.”

Devana Solutions now boasts integrations with several leading CTMS technologies on the market. These integrations speak to more than just added convenience and increased efficiencies; they’re speeding up the clinical trial process resulting in improved clinical outcomes and therapies to patients.

About Devana Solutions

Decentralized clinical trials and work-from-anywhere is now a reality. Devana Solutions innovative cloud platform supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems. From pipeline administration to rapid study startup automation. From document-sharing through the capture, display, analysis, and exchange of key trial performance metrics data from central research leaders to decentralized trial teams. From investigative site to CRO to trial sponsor, Devana Solutions is the answer. At Devana Solutions, we’re transforming the business of clinical trials. https://devanasolutions.com/

About Advarra

Advarra makes clinical research safer, smarter, and faster. Our integrated solutions help safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance for over 3,500 sponsors, CROs, institutions, academic medical centers, and research consortia.

With trusted and unequaled independent oversight committee services, innovative software solutions for sites, sponsors, and CROs, and experienced consultants with deep-seated connections across the industry, Advarra has the expertise and technology needed to advance clinical research and help our clients make the world a healthier place.

Headquartered in Columbia, Maryland, Advarra’s extensive geographic reach helps clients navigate the evolving research and regulatory environment. https://www.advarra.com/

Accel Research Sites makes clinical trials more accessible with Devana Solutions’ PROPEL platform

Chapel Hill (February 22, 2022) – Accel Research Sites is bringing clinical trials to even more patients, right where they live and work, thanks to an industry-leading clinical trial platform from Devana Solutions.

Accel is the latest clinical trial network to convert to Devana’s PROPEL Enterprise Platform, which will help the organization connect central teams to site-based staff and clinicians. The company previously used Devana’s IGNITE platform to automate workflow at the start of studies and to gain insight into performance metrics.

“PROPEL literally brings the site to the patient,” according to Barry Lake, Devana Solutions’ CEO and Co-Founder. “Like most leading research site networks, our Accel client-partner has used our IGNITE technology to standardize the trial startup workflows and analytics for their central operations team but, with PROPEL, Accel’s clin-ops professionals collaborate in a common cloud with their site-based colleagues, providing patients with access to trials in the communities where they live and work. We are thrilled that the team at Accel is leading this transformational shift.”

Accel will use PROPEL to connect the centralized management team in Florida with clinicians across 24 sites. With the shift from IGNITE, Accel will see increased efficiencies and precision around site selection, as well as faster site startup and exceptional trial execution.

“When the pandemic hit, we at Accel had to reimagine many of our normal processes so we could both help with the global health crisis and continue to keep our participants healthy and safe,” said Lora Parahovnik, CEO. “Working with Devana has helped us become more efficient. We’re looking forward to continuing to push forward in clinical trial operations by leaning on a cutting-edge platform like PROPEL.”

Devana Solutions is a market leader in clinical trial SaaS for study startup automation, metrics capture and analytics. Accel has been a partner since 2019, recently moving to the PROPEL platform as the company has grown.

For more information about Devana Solutions, visit https://devanasolutions.com/. For more information about Accel Research Sites, visit https://accelresearchsites.com/.

About Devana Solutions

Decentralized clinical trials and work-from-anywhere is now a reality. Devana Solutions innovative cloud platform supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems. From pipeline administration to rapid study startup automation. From document-sharing through the capture, display, analysis, and exchange of key trial performance metrics data from central research leaders to decentralized trial teams. From investigative site to CRO to trial sponsor, Devana Solutions is the answer. At Devana Solutions, we’re transforming the business of clinical trials.

About Accel Research Sites

Accel Research Sites is a multi-therapeutic network of clinical research sites dedicated to the expert delivery of treatment options to patients and providers. They partner with the most innovative and significant pharmaceutical, biotechnology, and medical device companies worldwide to advance healthcare and wellness in the communities they serve.

SCOPE 2022 Recap: Takeaways from Clinical Ops Executives

The 2022 Summit for Clinical Operations Executives (SCOPE) has come to a close. Clinical operations executives from all parts of North America gathered in Orlando, Florida, to share the latest innovations in clinical trial recruitment, management, and analysis. Devana Solutions CEO and Co-Founder Barry Lake and Vice President of Operations Linda Parks attended the event to keep up with the latest trends and share how Devana Solutions’ cutting-edge platforms help pharmaceutical sponsors and clinical research organizations keep up with the rapid pace of technology adoption.

Our CTMS partners exhibiting were kind enough to refer Devana Solutions as a complementary platform to those stopping by their booths with a need for business development or startup solutions. Special shout-out to Elise Tawfiq of RealTime CTMS, as well as Mia Castagnero and Eric Elander of Clinical Research IO (CRIO) and the entire CRIO team for their hospitality.

We started the week by making history teeing off at SCOPE’s Inaugural Masters of Clinical Research Golf Tournament.

 

 

In between speakers and breakout sessions, the week was filled with talks from industry thought leaders and networking opportunities with colleagues. Since the first day, we were fortunate to spend time discussing the challenges of and solutions to patient recruitment in multisite studies with Trialbee CEO Matt Walz.

We congratulated Rick Riegel, for becoming the most recent member to join the Board of Directors at RealTime CTMS. We know that he will be a great asset to our friends at RealTime CTMS.

Although the clinical research industry is driven by technology, it’s the face-to-face interactions at conferences like these that put our work into perspective: “people caring for people.”

SCOPE 2022 Recap: Takeaways from Clinical Ops Executives with Devana Solutions
From left to right: Centricity CEO and Co-Founder of hyperCORE Jeff Kingsley and Devana Solutions Vice President of Operations Linda Parks at the hyperCORE Kick-Off Luau

 

We met with Jill Johnson, President of WCG’s Clinical Services Organization, to celebrate her study planning and site optimization efforts! Using Devana Solutions PROPEL Enterprise Platform’s ability to provide reliable real-time and historic metrics, WCG can ascertain predictable study performance data by directly connecting their research sites and effortlessly manage study feasibility, track study workflow and milestone completion, and oversee site facilities and equipment.

Lastly, we always enjoy spending time discussing how our companies are innovating and leading the clinical trial space with Florence Healthcare CEO Ryan Jones.

“Year after year, we’re seeing the use of technology in drug development continuing at a breakneck pace. The way we conduct research has changed drastically because of it, and there’s no doubt that this trend will continue,” said Lake.

 

 

Vice President of Operations Linda Parks agrees. Thanks to innovations in data technologies, the world of clinical data management and analytics has seen some impressive advancements in recent years. If you’re looking to stay ahead of the curve with the digitization of healthcare data and its cloud storage, then you need to be able to seamlessly share and analyze performance levels across your entire research network.

“More than sites needing a platform that can keep up with the latest trends, they need a platform that can display actionable data in real-time,” said Parks.

It’s clear that Devana Solutions is the category leader when it comes to innovation in the field of pipeline administration, study startup workflow automation, metric analysis, and data visualization. Thanks to Devana Solutions, clinical trials are becoming more efficient every day.

1 2 3 4